Performance of the Aptima High-Risk Human Papillomavirus mRNA Assay in a Referral Population in Comparison with Hybrid Capture 2 and Cytology
- 1 March 2011
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 49 (3), 1071-1076
- https://doi.org/10.1128/jcm.01674-10
Abstract
This study compared the Aptima human papillomavirus (HPV) (AHPV; Gen-Probe Incorporated) assay, which detects E6/E7 mRNA from 14 high-risk types, the Hybrid Capture 2 HPV DNA (HC2; Qiagen Incorporated) test, and repeat cytology for their ability to detect high-grade cervical lesions (cervical intraepithelial neoplasia grade 2+ [CIN2+]) in women referred to colposcopy due to an abnormal Papanicolaou (Pap) smear. A total of 424 clinical specimens, stored in liquid-based cytology (LBC) vials at room temperature for up to 3 years, were tested by repeat cytology, the AHPV assay, and the HC2 test. Assay results were compared to each other and to histology results. The overall agreement between the AHPV assay and the HC2 test was 88.4%. The sensitivity (specificity) of cytology, the HC2 test, and the AHPV assay for the detection of CIN2+ was 84.9% (66.3%), 91.3% (61.0%), and 91.7% (75.0%) and for the detection of CIN3+ was 93.9% (54.4%), 95.7% (46.0%), and 98.2% (56.3%), respectively. Of the disease-positive specimens containing high-risk HPV (HR HPV) DNA as determined by Linear Array (Roche Diagnostics), the AHPV assay missed 3 CIN2 and 1 microfocal CIN3 specimen, while the HC2 test missed 6 CIN2, 4 CIN3, and 1 cervical carcinoma specimen. The AHPV assay had a sensitivity similar to but a specificity significantly higher ( P < 0.0001) than the HC2 test for the detection of CIN2+. The AHPV assay was significantly more sensitive ( P = 0.0041) and significantly more specific ( P = 0.0163) than cytology for the detection of disease (CIN2+).This publication has 25 references indexed in Scilit:
- Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid‐based cytology in primary cervical cancer screening: The FASE studyInternational Journal of Cancer, 2010
- Human Papillomavirus Types 16 and 18 mRNA Levels and Not DNA Levels May be Associated With Advancing Stages of Cervical CancerInternational Journal of Gynecologic Cancer, 2009
- Clinical performance of the APTIMA® HPV Assay for the detection of high-risk HPV and high-grade cervical lesionsJournal of Clinical Virology, 2009
- Efficiency of the APTIMA® HPV Assay for detection of HPV RNA and DNA targetsJournal of Clinical Virology, 2009
- Comparison of Predictors for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal SmearsCancer Epidemiology, Biomarkers & Prevention, 2008
- Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screeningInternational Journal of Cancer, 2008
- 2006 consensus guidelines for the management of women with abnormal cervical cancer screening testsAmerican Journal of Obstetrics and Gynecology, 2007
- Human Papillomavirus and Papanicolaou Tests to Screen for Cervical CancerThe New England Journal of Medicine, 2007
- HPV prevalence, viral load and physical state of HPV‐16 in cervical smears of patients with different grades of CINInternational Journal of Cancer, 2007
- The Significance of Human Papillomavirus Viral Load in Prediction of Histologic Severity and Size of Squamous Intraepithelial Lesions of Uterine CervixGynecologic Oncology, 2001